*BI-1208.22



A double-blind, stratified, randomised, parallel, placebo-controlled, multi-centre study to assess the efficacy and safety of duloxetine (20 mg bid for 2 weeks escalating to 40 mg bid) for up to 12 weeks, compared to placebo, in community-dwelling elderly women >= 65 years of age with symptoms of stress urinary incontinence or stress-predominant mixed urinary incontinence
duloxetine hydrochloride
1208.22
NCT00244296
Urinary Incontinence, Stress
Phase 4
 
The study was sponsored by Boehringer Ingelheim; the license holder is Lilly.
January 2015